Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches

The world’s generic drug leader has cemented its leadership position for the foreseeable future with the acquisition of Allergan’s generics business. Management outlined how it plans to grow the combined business by taking advantage of its size during an investor briefing.